Bristol-Myers Squibb Stock News

Bristol Myers' stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer's treatment, even though the outcome of a late-stage trial has been delayed.

LOS ANGELES--(BUSINESS WIRE)-- #biotech--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb.

Bristol Myers Squibb stock popped Wednesday after the firm delayed a study testing Cobenfy in Alzheimer's disease psychosis.

The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer's disease.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease.

John Buckingham, editor of the Prudent Speculator, reminds investors to be “willing to stomach volatility.”

A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.

Bristol Myers Squibb (BMY) is finally showing signs of life. The stock has climbed 7.3% over the last five days, adding roughly $7 billion in market value — pushing its market cap back toward $100 billion.